Webinars

Circular RNA (circRNA) is an emerging RNA modality within the advanced therapy medicinal product (#ATMP) landscape, offering the potential for durable protein expression, enhanced stability, and reduced immunogenicity and toxicity compared with linear mRNA. CircRNA therapeutics may also enable fewer dosing requirements, cost-efficient enzyme-free downstream processing, and a potentially faster path toward clinical development following IND clearance.

Despite these advantages, developing and manufacturing circRNA–LNP therapeutics presents unique challenges, including achieving high circularization efficiency and purity, optimizing LNP formulation, and demonstrating sustained in vivo expression through fit-for-purpose analytical methods.

In this joint webinar, uBriGene Biosciences and Circurna will present complementary capabilities to support circRNA programs from discovery to clinical translation. uBriGene will highlight process development, scalable GMP manufacturing, and analytical strategies addressing key CMC challenges, while Circurna will introduce its ciRNA™ platform, including circular RNA design, payload optimization, and delivery approaches.

The session will also share practical insights into circRNA purification, circRNA-LNP formulation, and emerging trends shaping the future of circRNA therapeutics.

Lentiviral vector supply remains one of the most significant bottlenecks for CAR-T and gene-modified cell therapy programs. In this webinar, uBriGene and Syenex will introduce two complementary platform technologies - uBriGene’s high-productivity LVV Turbo™ manufacturing system and Syenex’s Ultra-T enhancer. Together, LVV Turbo™ + Ultra-T can deliver thousands of CAR-T doses from a 20 L production run.

The session will feature a technical deep dive into LVV upstream productivity, downstream closed process, and enhanced T-cell targeting, followed by a moderated discussion with a client who has adopted these innovations and will share clinical benefits.

Attendees will learn how these cutting-edge technologies can alleviate lentiviral supply constraints, reduce manufacturing costs, and support seamless scale-up from early development through commercial readiness.

uBriGene Biosciences delivers high efficiency total solution designed to accelerate the development of iPSC-derived cell therapies.

In this webinar, you’ll discover uBriGene’s expanding portfolio of iPSC innovations, including:

• Proprietary RNA-LNP v1 and v2 technologies – Explore the latest reprogramming technologies and processes.
• GMP iPSC Line Banks – Access fully characterized iPSC lines with supporting Drug Master Files to speed clinical development.
• Differentiation Capabilities – Learn about the differentiation of iPSCs into clinically relevant functional cell types including neurons, pancreatic islet cells, and skeletal muscles.
• End-to-End GMP iPSC Platform – An integrated solution for reprogramming, engineering, banking, and manufacturing tailored to clinical needs.

Join us to see how uBriGene’s solutions can accelerate the development of iPSC-based therapeutics, advancing the next generation of cell therapies and disease models.

The development of induced pluripotent stem cells (iPSCs) has opened new frontiers in disease modeling and cell therapy, but the expertise required to harness their full potential has traditionally posed significant barriers. uBriGene Biosciences is committed to overcoming these challenges by offering high-quality, time-saving solutions that accelerate the clinical impact of iPSC technologies.

In this webinar, you'll learn about uBriGene’s innovative portfolio, which includes:

• High-Efficiency mRNA-LNP iPSC Reprogramming Cocktail: cutting-edge solution to streamline and improve iPSC reprogramming efficiency.
• GMP iPSC Line Banks: Fully characterized iPSC lines, accompanied by drug master files, to accelerate the development of allogeneic cell therapies.
• Comprehensive GMP iPSC Platform: An integrated solution for iPSC reprogramming, engineering, banking, and manufacturing, designed to meet the needs of clinical applications.

Join us to explore how uBriGene's solutions can fast-track the development of iPSC-based therapeutics, facilitating the next generation of disease models and cell therapies.

CRISPR technology has rapidly evolved from a Nobel Prize-winning discovery to a groundbreaking genetic medicine, exemplified by the recent approval of Casgevy for sickle cell disease. While CRISPR holds immense potential to treat various genetic diseases, manufacturing challenges remain a key hurdle. uBriGene has developed a pioneering in vitro transcription (IVT) sgRNA manufacturing platform that addresses limitations in scalability, quality control, sgRNA length, and environmental sustainability.

What you'll learn in this webinar:

• Insights into uBriGene’s innovative IVT sgRNA manufacturing platform.
• Solutions to overcome technical challenges in traditional solid-phase chemistry workflows.
• How uBriGene’s integrated platforms accelerate clinical success.

RNA-based therapy has been an expanding area of clinical research since the COVID-19 outbreak. Beyond vaccines, RNA therapies are now being developed to treat a growing number of disease indications. The rapid advancement of RNA drugs has taken various forms, including siRNA, sgRNA, mRNA, circRNA, and saRNA.

In this webinar, we will explore the fundamentals of RNA drug development and the critical role of in vitro transcription (IVT) in manufacturing workflows.

What You’ll Learn:

• Basics of RNA drug development and the current landscape.
• Overview of GMP manufacturing workflows for RNA therapies.
• Key aspects of in-process and release testing panels.

This session is perfect for professionals looking to deepen their understanding of RNA manufacturing processes and ensure their workflows are GMP-compliant.

The goal of this webinar is to:

• Understand the basics of Lentiviral Vector (LV): definition and characteristics of LV, and their mechanism of action in gene-modified cell therapies.
• Explore current manufacturing approaches for LV: an overview of existing platforms and technologies, as well as key considerations in LV production scalability and efficiency.
• Discuss strategies to accelerate LV deployment in cell therapy: the importance of early identification of critical raw materials, and criteria for selecting a proven manufacturing platform, also impact on time-to-market and therapeutic accessibility.

In the first presentation, you will gain a comprehensive understanding of CAR-T therapies, including:

• The general requirements for the development of CAR-T therapies
• General approaches to gene modification of T-cells
• High level discussion of GMP manufacturing workflows
• Regulatory considerations for clinical application of these therapies